<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959374</url>
  </required_header>
  <id_info>
    <org_study_id>SYN08003</org_study_id>
    <nct_id>NCT00959374</nct_id>
  </id_info>
  <brief_title>Evaluation of Dermal Closure With an Absorbable Barbed Suture as Compared to a Conventional Absorbable Suture</brief_title>
  <official_title>A Prospective, Randomized Study to Evaluate Dermal Closure With an Absorbable Barbed Suture (V-Loc 180 Absorbable Wound Closure Device or V-Loc 90 Absorbable Wound Closure Device) as Compared to a Conventional Absorbable Suture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the use of an absorbable barbed suture as compared
      to a conventional absorbable suture when used for dermal closure during certain body
      contouring procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One of the greater common challenges of a surgical procedure is to effectively and
      efficiently close wounds across various levels of muscle, fat, fascia and/or skin.

      Surgical sutures continue to be the material of choice for wound closure. However,
      complications of sutures are those associated with tying knots to secure the suture. Examples
      of associated suture complications, although not comprehensive, include knot breakage and
      slippage, suture extrusion or spitting, infection, ischemia and scarring, reduced wound
      strength and inflammation and dehiscence.

      Both interrupted and continuous suture patterns require knots for suture line security when
      conventional suture constructs are used. Barbed sutures are designed to eliminate the need
      for tying knots during closure, thus ameliorating the detrimental aspects of knots.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Dermal Closure Time</measure>
    <time_frame>At time of surgery</time_frame>
    <description>In calculating the total dermal closure time, only the intradermal closure time is used for those subjects that did not have the deep dermal layer closed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmesis</measure>
    <time_frame>12 weeks</time_frame>
    <description>Photographs of scars were obtained at 12 week visit and reviewed by a independent blinded plastic surgeon. The blinded assessor scored four elements of scar appearance on a scale of 1 to 5 each, including color match, width, borders and edges, and contour and distortion. On this scale, 1 = worst, 2= poor, 3= average, 4=good and 5=excellent. For the purpose of analysis, all scores for a patient were summed into a single composite score (4-20).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">229</enrollment>
  <condition>Breast Ptosis</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>V-loc and Monocryl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects served as their own control, and they were randomized to receive an intervention of a standard closure using 3-0 Monocryl™ on one side of the body and the test closure device, V-Loc 180/90, on the other side. The standard closure technique was agreed on by study investigators for control side, and included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl™ sutures, spaced no further than 2 cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl™ sutures. The test closure side, closure of the deep dermal layer was optional. If deep dermal sutures were used, interrupted 3-0 Monocryl™ sutures were required to be placed no closer than 5 cm apart followed by closure of the intradermal layer with test device, V-Loc 180/90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>V-Loc 180/90 Wound Closure Device</intervention_name>
    <description>Barbed absorbable suture</description>
    <arm_group_label>V-loc and Monocryl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3-0 Monocryl Absorbable Sutures</intervention_name>
    <description>3-0 Monocryl Absorbable Suture (non-barbed)</description>
    <arm_group_label>V-loc and Monocryl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must be 18 years of age or older.

          -  Subject must be in good overall health.

          -  Subject must be scheduled for individual or combined abdominoplasty, reduction
             mammaplasty, or mastopexy, other than concentric mastopexy, crescent mastopexy, or
             mastopexy with implants.

          -  Subject must be willing to participate in the study, comply with study requirements,
             follow-up schedule, and give written informed consent.

        Exclusion Criteria:

          -  Subject is pregnant or breast-feeding.

          -  Subject has active infectious collagen diseases (i.e. scleroderma) or any other
             condition that would interfere with wound healing.

          -  Subject has significant anatomic asymmetry that creates markedly different wound
             tension and/or geometry between the right and left side.

          -  Subject is allergic to the test suture made of glycolide and trimethylene carbonate or
             the control suture made of glycolide and epsilon-caprolactone.

          -  Subject has a BMI ≥ 40.

          -  Subject has diabetes requiring medication for glycemic control.

          -  Subject has a fever (temperature &gt; 38ºC), active skin infection or systemic infection
             at the time of surgery.

          -  Subject underwent chemotherapy or radiation within the last 6 months.

          -  Subject has a history of keloid or hypertrophic scar formation or other dermatologic
             conditions known to impair wound healing.

          -  Subject has a history of alcohol or drug abuse within 6 months prior to screening.

          -  Subject has a history of immunosuppressive drug use, including steroids, within the
             last 6 months.

          -  Subject has had a documented breast imaging finding or physical breast exam finding
             requiring further evaluation prior to elective surgery.

          -  Subject has not had a mammogram within the last 12 months, for female patients ≥ 40
             years of age scheduled for mastopexy or reduction mammaplasty.

          -  Subject is taking part in another clinical study which directly relates to this study.
             If, however, the subject is taking part in a non-related study, the investigator
             should contact the Study Manager for advice.

          -  The investigator determines that the subject should not be included in the study for
             reasons not already specified.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hunstad Center for Cosmetic Plastic Surgery</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Frauenklinik</city>
        <state>Bonn</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Stuttgart</name>
      <address>
        <city>Boheimstrasse</city>
        <state>Stuttgart</state>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <results_first_submitted>August 29, 2012</results_first_submitted>
  <results_first_submitted_qc>March 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2013</results_first_posted>
  <last_update_submitted>March 6, 2013</last_update_submitted>
  <last_update_submitted_qc>March 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Abdominoplasty</keyword>
  <keyword>Reduction Mammaplasty</keyword>
  <keyword>Mastopexy</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject was consented 12Aug2009 and last subject final follow up visit 15May2011. 241 subjects were enrolled from 9 sites in the USA and Europe. Of those, 229 were consented, randomized and treated. All subjects were volunteers scheduled for individual or combined abdominoplasty, mastopexy or reduction mammaplasty.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>V-loc and Monocryl</title>
          <description>Each subject served as their own control and was randomized as to which side of the body received the test procedure. On the test closure side, the investigator could elect not to close the deep dermal layer, but if the deep dermal layer was closed, interrupted 3-0 Monocryl(TM) sutures were required to be placed no more than 5cm apart. Following optional closure of deep dermal layer, the intradermal layer was closed with running V-Loc(TM)90 or 180 device. The study was initiated with V-Loc(TM)180 as the only test device and V-Loc(TM)90 was added via protocol amendment 13Apr2010.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="241">Of the 241 enrolled subjects, 229 were randomized and treated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Implant Removed/Not Replaced</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V-loc and Monocryl</title>
          <description>All randomized subjects</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical Procedure</title>
          <description>Must be scheduled for individual or combined abdominoplasty, mastopexy or reduction mammaplasty</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Dermal Closure Time</title>
        <description>In calculating the total dermal closure time, only the intradermal closure time is used for those subjects that did not have the deep dermal layer closed.</description>
        <time_frame>At time of surgery</time_frame>
        <population>Includes only those subjects where a deep dermal layer was closed.</population>
        <group_list>
          <group group_id="O1">
            <title>V-Loc 180 / 90 Wound Closure Device</title>
            <description>Each subject served as their own control and was randomized as to which side of the body received the test procedure. On the test closure side, the investigator could elect not to close the deep dermal layer, but if the deep dermal layer was closed, interrupted 3-0 Monocryl(TM) sutures were required to be placed no more than 5cm apart. Following optional closure of deep dermal layer, the intradermal layer was closed with running V-Loc(TM)90 or 180 device. The study was initiated with V-Loc(TM)180 as the only test device and V-Loc(TM)90 was added via protocol amendment 13Apr2010.</description>
          </group>
          <group group_id="O2">
            <title>3-0 Monocryl Sutures</title>
            <description>Each Subject served as their own control and was randomized to which side of the body received the control sutures. The control side included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl(TM)sutures, spaced no further than 2cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl(TM) sutures.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Dermal Closure Time</title>
          <description>In calculating the total dermal closure time, only the intradermal closure time is used for those subjects that did not have the deep dermal layer closed.</description>
          <population>Includes only those subjects where a deep dermal layer was closed.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" spread="4.6"/>
                    <measurement group_id="O2" value="19.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cosmesis</title>
        <description>Photographs of scars were obtained at 12 week visit and reviewed by a independent blinded plastic surgeon. The blinded assessor scored four elements of scar appearance on a scale of 1 to 5 each, including color match, width, borders and edges, and contour and distortion. On this scale, 1 = worst, 2= poor, 3= average, 4=good and 5=excellent. For the purpose of analysis, all scores for a patient were summed into a single composite score (4-20).</description>
        <time_frame>12 weeks</time_frame>
        <population>Subjects who did not return for the 12 week follow-up visit were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>V-Loc 180 / 90 Wound Closure Device</title>
            <description>Each subject served as their own control and was randomized as to which side of the body received the test procedure. On the test closure side, the investigator could elect not to close the deep dermal layer, but if the deep dermal layer was closed, interrupted 3-0 Monocryl(TM) sutures were required to be placed no more than 5cm apart. Following optional closure of deep dermal layer, the intradermal layer was closed with running V-Loc(TM)90 or 180 device. The study was initiated with V-Loc(TM)180 as the only test device and V-Loc(TM)90 was added via protocol amendment 13Apr2010.</description>
          </group>
          <group group_id="O2">
            <title>3-0 Monocryl Sutures</title>
            <description>Each Subject served as their own control and was randomized to which side of the body received the control sutures. The control side included mandatory closure of the deep dermal layer with interrupted 3-0 Monocryl(TM)sutures, spaced no further than 2cm apart, followed by closure of the intradermal layer with running 3-0 Monocryl(TM) sutures.</description>
          </group>
        </group_list>
        <measure>
          <title>Cosmesis</title>
          <description>Photographs of scars were obtained at 12 week visit and reviewed by a independent blinded plastic surgeon. The blinded assessor scored four elements of scar appearance on a scale of 1 to 5 each, including color match, width, borders and edges, and contour and distortion. On this scale, 1 = worst, 2= poor, 3= average, 4=good and 5=excellent. For the purpose of analysis, all scores for a patient were summed into a single composite score (4-20).</description>
          <population>Subjects who did not return for the 12 week follow-up visit were excluded from the analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.7" spread="2.8"/>
                    <measurement group_id="O2" value="13.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>V-Loc 180 / 90</title>
          <description>Within-patient study. Each patient received either V-Loc 180 or 90 on one side and the control suture (3-0 Monocryl)on the other side.</description>
        </group>
        <group group_id="E2">
          <title>Control - Monocryl 3-0</title>
          <description>Within-patient study. Each patient received either V-Loc 180 or 90 on one side and the control suture (3-0 Monocryl)on the other side.</description>
        </group>
        <group group_id="E3">
          <title>Midline</title>
          <description>Within-patient study. Each patient received either V-Loc 180 or 90 on one side and the control suture (3-0 Monocryl)on the other side. Events in this group occurred at midline incision and therefore not assigned to a treatment arm.</description>
        </group>
        <group group_id="E4">
          <title>Non-protocol Incision or Systemic Events</title>
          <description>Within-patient study. Each patient received either V-Loc 180 or 90 on one side and the control suture (3-0 Monocryl)on the other side. Events in this group occurred at either a non-protocol incision or were systemic in nature.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory/Cardiac Arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other - ecchymosis, light headedness and nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Bleeding Artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence (Adjudicated to Yes)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Abcess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="229"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="229"/>
                <counts group_id="E4" subjects_affected="84" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other - ecchymosis, light headedness and nausea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" events="57" subjects_affected="57" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="229"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="229"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Suture Extrusion</sub_title>
                <description>Suture extrusion without purulent discharge or abcess</description>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="229"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E4" events="21" subjects_affected="21" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <description>Adjudicated and required surgery</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <description>Did NOT require surgery</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="229"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Suture Extrusion</sub_title>
                <description>with purulent drainage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Incision Pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="229"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amy Pollack M.D. Vice President Medical Affairs, STI</name_or_title>
      <organization>Covidien</organization>
      <phone>203-821-4719</phone>
      <email>amy.pollack@covidien.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

